The Global Cell Line Development Industry is on a trajectory of exceptional growth, with a forecasted valuation of US$ 5.06 billion in 2023, and an impressive projected Compound Annual Growth Rate (CAGR) of 7.7% from 2023 to 2033. By the end of this forecast period, the market is expected to achieve a staggering worth of US$ 10.6 billion.
This remarkable growth can be attributed to the increasing utilization of bio-therapeutics in the treatment of chronic diseases such as arthritis, diabetes, and cancer. The demand for automated cell line development and cell line development services is consequently experiencing an unprecedented surge.
Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-7566
The rapid increase in the prevalence of cancer and neurology disorders and the lack of efficient treatment solution for these diseases has created the need for more advanced and efficient treatment pathways. Companies and government organizations are investing in research and development activities and are also focusing more on cell line development in search of new cellular pathways to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide a boost to the cell line development industry.
In recent times contract research organizations have been focusing on cell line development and cell line research activities. According to the National Institutes of Health (NIH), the estimated total federal spending on all types of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, the government is supporting cell line development through national funding agencies like the Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), and the Department of Science and Technology (DST).
Regenerative medicines are the next-generation treatment solution and Cell Line Development or Cell Culture is a vital part of regenerative medicine. Increasing demand for regenerative medicines in cancer treatment would positively impact the growth of the Cell Line Development industry over the forecast period.
The biopharmaceutical companies operating in the development of novel drug lines are expected to hold promising revenue opportunities in the cell line development industry.
Future Market Insights (FMI) has segmented the cell line development industry based on product type, cell line source type, end user, type of cell line, and region.
Product type segment in the cell line development industry is segmented into media and reagents, equipment, and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. The reagent and media segment in the cell line development market is expected to witness noteworthy growth in terms of revenue owing to a rapid increase in demand for cell culture and cell-based assays.
Cell line development industry by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipated to witness significant growth in the overall cell line development industry. This growth of the mammalian cells segment in the cell line development industry is driven by increased production of biologics drugs that require mammalian cells. Increasing antibody production is the major driving factor behind the growth of the mammalian cell lines segment in the cell line development industry.
Shedding light on the study’s key assumptions. Expert Guidance!
https://www.futuremarketinsights.com/ask-question/rep-gb-7566
Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. For example, Gaucher’s disease is a genetic disorder characterized by a lack of β-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produced in mammalian cell lines. Mammalian cell lines are also useful in the production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease-causing agents in the body. For example Under the cell line type segment in the cell line development market, recombinant cell line development is the most demanding type of cell line due to its large application in biologics production, protein interaction, gene activation, toxicity testing, and drug screening.
Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period
North America and Europe’s cell line development industry will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development industry is expected to grow at a high growth rate due to the increased number of research organizations engaged in novel biologics and biosimilars fastest revenue growth in the overall cell line development industry.
The Asia Pacific region in the Cell line development market is anticipated to witness increasing demand for biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development industry.
FMI’s report tracks some of the key companies operating in the cell line development industry, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/7566
Key Market Segments Covered in Cell line deLine Developmentry Research By Product Type:
- Reagent and Media
- Equipment
- Accessories and consumables
By Source Type:
- Mammalian cell line
- Non-mammalian cell line
By End User:
- Biopharmaceutical Companies
- Contract Research Organizations
- Academics and Research Institutes
- Biotechnology Companies
By Cell Lines:
- Recombinant cell lines
- Hybridomas
- Continuous cell lines
- Primary cell lines
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube